| 36th week of 2015 patent applcation highlights part 6 |
| Patent application number | Title | Published |
|---|
| 20150246057 | Metalloporphyrin Neurological Treatments - Methods and compositions for treating a subject suffering from exposure to a chemical threat agent are disclosed. | 2015-09-03 |
| 20150246058 | COMPOSITION FOR PREVENTING HAIR LOSS AND ACCELERATING HAIR GROWTH - Disclosed is a composition for prevention of hair loss and promotion of hair growth. The composition includes a compound represented by Formula 1, wherein A is derived from polycyclic compounds, and R is a hydroxyl group, or a saturated or unsaturated straight or branched alkyloxy or acyloxy group having 1 to 20 carbon atoms. | 2015-09-03 |
| 20150246059 | NITRATED LIPIDS AND METHODS OF MAKING AND USING THEREOF - Described herein are nitrated lipids and methods of making and using the nitrated lipids. | 2015-09-03 |
| 20150246060 | Abiraterone Acetate Formulation and Methods of Use - Pharmaceutical compositions, including unit dosage forms, comprising abiraterone acetate and methods for producing and using such compositions are described. | 2015-09-03 |
| 20150246061 | VITAMIN D ANALOGUES FOR THE TREATMENT OF A NEUROLOGICAL DISORDER - Disclosed herein are methods that use a vitamin D analogue to treat a neurological disorder. Additionally, pharmaceutical compositions comprising a vitamin D analogue and a neurotherapeutic agent are disclosed, and methods of using the same. The pharmaceutical compositions and methods of the invention are useful for the treatment of a neurological disorder, for example, Alzheimer's disease, multiple sclerosis, Parkinson's disease, epilepsy, neuropathic pain, or other conditions that affect the central or peripheral nervous system of a subject. | 2015-09-03 |
| 20150246062 | VITAMIN D COMPOSITIONS AND METHOD OF ADMINISTERATION TO A HUMAN BEING - Composition of vitamin D in medium-chain triglycerides and use thereof in delivering a nutritional or therapeutic amount of vitamin D to a human being, particularly, an infant. The compositions are applied to an object, such as skin or in the case of an infant to a woman's nipple or pacifier from which the infant sucks off the composition. The method provides a more suitable, safer and efficient way of providing the human being with vitamin D. The compositions further comprise a free fatty acid and/or monoglyceride, oxidant preservative and, optionally, other vitamins. | 2015-09-03 |
| 20150246063 | ATX MODULATING AGENTS - Compounds of formula (I) can modulate the activity of autotaxin (ATX). | 2015-09-03 |
| 20150246064 | METHOD FOR TREATING HEMATOPOIETIC NEOPLASMS - This invention relates to methods for treating a hematopoietic neoplasm comprising administering a therapeutically effective amount of a combretastatin compound, or a pharmaceutically acceptable salt thereof, to a subject having a hematological malignancy, wherein the combretastatin compound comprises a catechol or quinone moiety and is capable of forming a reactive oxygen species (ROS) in vivo. The method may further comprise co-administering a second chemotherapeutic agent. | 2015-09-03 |
| 20150246065 | Topical Pharmaceutical Composition - The present invention relates in general to a topical pharmaceutical composition comprising an antiretroviral agent in combination with a bactericidal agent and optionally an antifungal agent, particularly for use as a contraceptive. | 2015-09-03 |
| 20150246066 | NUTRITIONAL SUPPLEMENT - A solid nutritional supplement formulation comprises at least 60 wt % dextrose combined with creatine and/or Branched Chain Amino Acids (BCAA's). | 2015-09-03 |
| 20150246067 | ANTIVIRAL TREATMENT OF LYMPHOMA AND CANCER - The present invention provides compositions and methods to treat lymphoma and cancer. In particular, the present invention provides treatment of lymphoma and cancer using anti-HERV-K(HML-2) therapies. The present invention further provides compositions and methods for characterizing patient samples to, for example, select or identify therapeutic options or assess the impact of therapies. | 2015-09-03 |
| 20150246068 | NOVEL NUCLEOTIDE PRODRUG COMPOUNDS AND USE - Embodiments of the present invention include nucleoside 5′-monophosphate derivative compounds, their preparation and their uses. In some embodiments, nucleoside 5′-monophosphate derivative compounds are useful to treat viral infections. | 2015-09-03 |
| 20150246069 | METHOD OF USING SEQUENCE OF ANTAGOMIR FOR DEVELOPING MEDICINE FOR INHIBITING ORAL CANCER CELLS FROM SPREADING - A method of using sequence of antagomiR for developing medicine for inhibiting oral cancer cells from spreading is provided with the steps of combining a sequence of antagomiR with active ingredient to prepare a medicine which is configured to administer to oral cavity grown with oral cancer cells so that both miR-196a and miR-196b of the sequence of antagomiR are configuring of developing medicine for curing oral cancer cells. The miR-196a has a sequence of 5′-UAGGUAGUUUCAUGUUGUUGGG-3′(SEQ.ID.NO.1). The miR-196b has a sequence of 5′-UAGGUAGUUUCCUGUUGUUGGG-3′(SEQ.ID.NO.2). | 2015-09-03 |
| 20150246070 | SORAFENIB-MICRORNA COMBINATION THERAPY FOR LIVER CANCER - A method of treating a subject having liver cancer can include administering a synthetic oligonucleotide to a subject having liver cancer, the oligonucleotide comprising a sequence that is at least 80% identical to at least one of SEQ ID NO:1-12 (e.g., a miR-34 or miR-215 mimic); and administering sorafenib to the subject, wherein the molar ratio of sorafenib:oligonucleotide administered to the subject is in the range of about 10-2000 (e.g., a ratio that provides a superior, for example synergistic or greater than additive, effect). | 2015-09-03 |
| 20150246071 | TREATMENT COMPOSITIONS - Compositions for and methods of treating diseases related to oxidative stress are described. | 2015-09-03 |
| 20150246072 | METHODS OF TISSUE GENERATION - Provided herein are methods for forming three-dimensional tissues in vivo. In one embodiment, provided herein is a method for forming a three-dimensional tissue in vivo, comprising depositing on a surface that is in or on a subject at least one composition that comprises cells. In another embodiment, provided herein is a method for forming a three-dimensional tissue in vivo, comprising depositing on a surface that is in or on a subject at least one composition that comprises cells and at least one composition that comprises an extracellular matrix (ECM). In another embodiment, provided herein is a method for forming a three-dimensional tissue in vivo, comprising depositing on a surface that is in or on a subject at least one composition that comprises cells, at least one composition that comprises an extracellular matrix (ECM), and at least one other additional components. | 2015-09-03 |
| 20150246073 | RENAL CELL POPULATIONS AND USES THEREOF - The present invention concerns enriched heterogeneous mammalian renal cell populations characterized by biomarkers, and methods of making and using the same. | 2015-09-03 |
| 20150246075 | METHODS FOR ENHANCING HEMATOPOIETIC STEM/PROGENITOR CELL ENGRAFTMENT - Described herein are methods for enhancing engraftment of hematopoietic stem and progenitor cells using compounds identified using a zebrafish model of hematopoietic cell engraftment. The compounds can be used to treat hematopoietic stem cells ex vivo prior to transplantation of the cells. Alternatively, the compounds can be administered to an individual undergoing cell transplantation. | 2015-09-03 |
| 20150246076 | EXTRACELLULAR MATRIX COMPOSITIONS FOR THE TREATMENT OF CANCER - The present invention is directed to methods of inhibiting cancer cell growth or proliferation by contacting the cancer cell with an extracellular matrix (ECM) composition. Also provided are methods of delivering a chemotherapeutic agent to a cancer cell by contacting a cancer cell with an extracellular matrix composition containing a chemotherapeutic agent. Also provided are compositions containing ECM and a chemotherapeutic agent. | 2015-09-03 |
| 20150246077 | Regeneration of Spinal Discs - Compositions and processes for the effective and efficient regeneration of spinal discs are provided. These compositions contain stem cells, donor cells, and platelet plasma compositions. By using these compositions, there is an increased likelihood of acceptance and proper cell differentiation. | 2015-09-03 |
| 20150246078 | TREATMENT OF PULMONARY ARTERIAL HYPERTENSION WITH MESENCHYMAL STEM CELLS - The application is directed to a method for treating or preventing vasculopathy comprising administrating to a subject in need thereof a pharmaceutical composition comprising mesenchymal precursor cells (MPCs) and a prostacyclin. Also provided a method for treating or preventing vasculopathy in a subject in need thereof, comprising administering to the subject a prostacyclin and a mesenchymal stem cell (MSC) or a MSC-conditioned culture medium or administering to the subject a MSC or a MSC-conditioned culture medium that has treated with prostacyclin. Pharmaceutical compositions suitable for such treatments are also provided. | 2015-09-03 |
| 20150246079 | IMMUNE PRIVILEGED AND MODULATORY PROGENITOR CELLS - Described herein is a method for modulating an immune reaction between lymphocytes and a body recognized by the lymphocytes as foreign. The method exploits the immunomodulating activity of a new class of progenitor cells termed HUCPVCs derived from the perivascular region of human umbilical cord. The method can also employ soluble factors exuded by cultured HUCPVCs. The method is useful to treat immune disorders including graft versus host disease, autoimmune disorders, and the like. | 2015-09-03 |
| 20150246080 | TREATMENT OF POST-TRAUMATIC STRESS DISORDER WITH ISOLATED MYCOBACTERIUM - The present invention relates to treatment or prevention of post-traumatic stress disorder (PTSD). In particular, the present invention relates to an isolated | 2015-09-03 |
| 20150246081 | PROBIOTICS WITH METHODS FOR GROWTH AND USE SEPARATELY AND IN COMBINATION - A dietary supplement that may contain probiotics from the genera | 2015-09-03 |
| 20150246082 | Pediococcus-Based Probiotics for Body Weight Control - A method of augmenting a weight-loss regimen composition comprising administering at least one billion | 2015-09-03 |
| 20150246083 | GENETICALLY MODIFIED PROBIOTIC FOR THE TREATMENT OF PHENYLKETONURIA (PKU) DISEASE - A GMP adapted to provide the PAL gene for the treatment of PKU when administered orally. The GMP of the present invention may include a probiotic, a PAL gene to be expressed using the probiotic, wherein the PAL gene is functionally attached to a promoter and a ribosome binding site, and may be codon-optimized for expression in a certain host organism. A method of treating the metabolic disease of PKU by oral administration and ingestion of a GMP is also provided. | 2015-09-03 |
| 20150246084 | COMPOSITION FOR REMOVING KERATINOUS SKIN MATERIAL COMPRISING GREEN TEA LACTOBACILLUS - The present invention relates to a composition for removing keratinous skin material, the composition comprising a | 2015-09-03 |
| 20150246085 | Genetically-Modified Probiotic for Treatment of Phenylketonuria - The present disclosure provides a genetically-modified probiotic expressing recombinent phenylalanine ammonia Lyase (PAL) useful for treating phenylketonuria. | 2015-09-03 |
| 20150246086 | Use of Mutant Herpes Simplex Virus-2 for Cancer Therapy - The present invention is directed to the composition and use of a modified Herpes Simplex Virus Type 2 (HSV-2) as a medicament in the treatment of cancer. The modified HSV-2 comprises a modified/mutated ICP10 polynucleotide encoding a polypeptide having ribonucleotide reductase activity and lacking protein kinase activity. | 2015-09-03 |
| 20150246087 | EXTRACTS AND THERAPEUTIC USES THEREOF - The invention relates to compositions and formulations comprising isolated fractions derived from Cupressaceae plant material. More particularly, the invention relates to pharmaceutical compositions comprising an isolated fraction of Cupressaceae in a carrier and use thereof for treating fibrotic conditions and neurodegenerative disorders. | 2015-09-03 |
| 20150246088 | PHARMACEUTICAL COMPOSITION FOR TREATING DIABETES CONTAINING QUAMOCLIT ANGULATA EXTRACT - Disclosed are a pharmaceutical composition for treating diabetes and its complications, containing a | 2015-09-03 |
| 20150246089 | SKIN SENSITIZER DELIVERY SYSTEM - A skin-sensitizing formulation is provided in an edible, softgel pill. A person engaged in a sexual activity bites down on the pill, thereby effectuating the oral release of the skin-sensitizing formulation. This allows the skin-sensitizing formulation to be spread to a sexual partner, on any part of the skin or sexual region of the body preferably through oral contact with the partner. The skin-sensitizing substance is spread to the partner directly on the skin or through oral contact or beneath a condom worn by the partner. The skin-sensitizing formulation may include an essential mint oil, analog or derivative, and may further includes an enhancer, rubefacient, counterirritant, anesthetic, K-Opoid Receptor activator, or TRPMS activator. Various inactive ingredients are also disclosed. | 2015-09-03 |
| 20150246090 | NON-DIGESTIBLE OLIGOSACCHARIDES FOR ORAL INDUCTION OF TOLERANCE AGAINST DIETARY PROTEINS - Compositions and methods for providing infant nutrition with partially hydrolysed proteins and non-digestible oligosaccharides for use in induction of oral tolerance against native dietary proteins. | 2015-09-03 |
| 20150246091 | COMPOUNDS AND METHODS FOR PREVENTING OR TREATING A VIRAL INFECTION - A compound is provided which has a structure I: A-B-C and a method for administering the compound is also provided for use in the prophylaxis and/or treatment of a viral infection, and in particular for preventing and/or inhibiting viral replication, in which A is a quinoline or quinoline-like group, B is a sole amino acid or a peptide or polypeptide having a given amino acid sequence, and C is an O-phenoxy group. According to one embodiment, the compound is a protease inhibitor such as a caspase inhibitor, and the inhibitor can be Q-VD-OPh (N-(2-(quinolyl)valylaspartyl-(2,6-difluorophenoxyl)methyl ketone), optionally in an O-methylated form. Antiviral compositions and kits are also provided. | 2015-09-03 |
| 20150246092 | METHODS FOR REDUCING RISKS ASSOCIATED WITH HEART FAILURE AND FACTORS ASSOCIATED THEREWITH - The disclosure provides methods of preventing or treating heart failure in a mammalian subject, reducing risk factors associated with heart failure, and/or reducing the likelihood or severity of heart failure. The disclosure also provides methods of preventing, or treating LV remodeling in a mammalian subject, and/or reducing the likelihood or severity of LV remodeling. The methods comprise administering to the subject an effective amount of an aromatic-cationic peptide. In some embodiments, the methods comprise administering to the subject an effective amount of an aromatic cationic peptide to reduce levels of C-reactive protein, tumor necrosis factor alpha, interleukin 6, reactive oxygen species, Nt-pro BNP, and/or cardiac troponin I, and/or reduce expression levels of MLCL AT1 and/or ALCAT 1 in subjects in need thereof. | 2015-09-03 |
| 20150246093 | ORAL FORMULATIONS OF ANGIOTENSIN - The present invention provides various formulations for oral delivery of angiotensin peptides. | 2015-09-03 |
| 20150246094 | USE OF LIGHT SENSITIVE GENES - The invention relates to the use of a light-gated ion channel for the manufacture of a medicament for the treatment of blindness and a method for expressing said cell specific fashion, e.g. in ON-bipolar cells, ON-ganglion cells, or AII amacrine cells. | 2015-09-03 |
| 20150246095 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE PROPHYLACTIC TREATMENT OF BACTERIAL SUPERINFECTIONS POST-INFLUENZA - The present invention relates to methods and pharmaceutical compositions for the prophylactic treatment of bacterial superinfections post-influenza. In particular, the present invention relates to an interleukin 22 (IL-22) polypeptide for use in the prophylactic treatment of bacterial superinfections post-influenza in a subject in need thereof. | 2015-09-03 |
| 20150246096 | Method for non-cancer disease treatment combining statin and interferon agents - A method for pharmacological treatment of cancer and other diseases is presented which includes the novel combination of a statin (Hmg-CoA reductase inhibitor, such as lovastatin, simvastatin, atorvastatin, cerivastatin, fluvastatin, pravastatin, or newer agents), with an interferon (such as interferon alfa-2b or others) or an angiogenesis inhibitor (a very similar and often overlapping group of drugs which inhibit blood vessel growth and maintenance, such as thalidomide, angiostatin, endostatin, or other agents), and also including concurrent administration of selenium and calcium. The method disclosed in this invention is useful because it can prove more effective than previously known therapies for certain diseases and because its use may be more tolerable, less disfiguring, and less expensive than other methods. The method here disclosed can be readily reproduced by any person skilled in the art of treating disease. | 2015-09-03 |
| 20150246097 | Polyalkylene Polymer Compounds and Uses Thereof - The invention relates to novel polyalkylene glycol compounds and methods of using them. In particular, compounds comprising a novel polyethylene glycol conjugate are used alone, or in combination with antiviral agents to treat a viral infection, such as chronic hepatitis C. | 2015-09-03 |
| 20150246098 | PEPTIDES AND METHODS FOR PREVENTING ISCHEMIC INJURY - Provided are GLP-1 C-terminal peptides and methods of use for the treatment or prevention of ischemic tissue injury. The peptides correspond to GLP-1(28-36). FIAWLVKGR and GLP-1(28-37) FIAWLVKGRG and are useful in the treatment or prevention of ischemic tissue injury, including ischemic heart disease or stroke | 2015-09-03 |
| 20150246099 | Use of Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway for the Treatment of Various Diseases - The present invention refers to the use of protein kinase inhibitors and more specifically to the use of inhibitors of the protein kinase c-Jun amino terminal kinase, JNK inhibitor sequences, chimeric peptides, or of nucleic acids encoding same as well as pharmaceutical compositions containing same, for the treatment of various diseases or disorders strongly related to JNK signaling, wherein these diseases or disorders are selected from autoimmune disorders, cardiovascular diseases, cancerous diseases, diabetes, including diabetes type 1 or type 2, inflammatory diseases, hair loss, including Alopecia areata, diseases of the lung, neuronal or neurodegenerative diseases, diseases of the liver, diseases of the spine, diseases of the uterus, viral infectious diseases and depressive disorders. | 2015-09-03 |
| 20150246100 | Modulation of Immune Function by Dietary Bovine Lactoferrin - The invention provides methods of increasing immune cell function in a newborn mammal that has not consumed any substantial amounts of colostrum or breast milk comprising administering an infant formula comprising about 1.0 to about 10 g/L of lactoferrin to the newborn mammal. | 2015-09-03 |
| 20150246101 | METHODS FOR ALLEVIATING SYMPTOMS OF MULTIPLE SCLEROSIS BASED ON APOAEQUORIN-CONTAINING COMPOSITIONS - Methods for alleviating symptoms related to Multiple Sclerosis by administration of apoaequorin are provided by the present invention. Such symptoms include, for example, sleep quality, energy quality, mood quality, memory quality or pain. | 2015-09-03 |
| 20150246102 | METHODS, COMPOSITIONS, AND DEVICES FOR SUPPLYING DIETARY FATTY ACID NEEDS - Nutritional formulas comprising long-chain polyunsaturated fatty acids (LC-PUFAs) are provided, along with methods and devices for preparing and/or administering nutritional formulas. In some embodiments, a percentage of the LC-PUFAs in the nutritional formula are in the form of monoglycerides and/or free fatty acids. In some embodiments, the nutritional formulas do not comprise added lipase. Also provided are methods for providing nutrition to a subject, methods for improving fat absorption, methods for improving cognitive ability, methods for preventing chronic lung disease, and methods for reducing the length of time a patient requires total parenteral nutrition. | 2015-09-03 |
| 20150246103 | CELL-FREE DNA AS A THERAPEUTIC TARGET FOR FEMALE INFERTILITY AND DIAGNOSTIC MARKER - The present invention pertains to the use of DNase to treat female infertility and the use of cfDNA as a marker of female infertility. | 2015-09-03 |
| 20150246104 | COMPOSITIONS AND METHODS FOR THE TREATMENT OR THE PREVENTION OF E. COLI INFECTIONS AND FOR THE ERADICATION OR REDUCTION OF E. COLI SURFACES - Compositions and methods for treating or preventing | 2015-09-03 |
| 20150246105 | COMPOSITIONS AND METHODS FOR TREATMENT OR PREVENTION OF STAPHYLOCOCCUS AUREUS INFECTIONS AND FOR THE ERADICATION OR REDUCTION OF STAPHYLOCOCCUS AUREUS ON SURFACES - Compositions and methods for treating or preventing | 2015-09-03 |
| 20150246106 | PROSTATE-ASSOCIATED ANTIGENS AND VACCINE-BASED IMMUNOTHERAPY REGIMENS - The present disclosure provides (a) isolated immunogenic PAA polypeptides; (b) isolated nucleic acid molecules encoding immunogenic PAA polypeptides; (c) vaccine compositions comprising an immunogenic PAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic PAA polypeptide; (d) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions; and (e) vaccine-based immunotherapy regimens which involve co-administration of a vaccine in combination with an immune-suppressive-cell inhibitor and an immune-effector-cell enhancer. | 2015-09-03 |
| 20150246107 | NOVEL LIVE ATTENUATED SHIGELLA VACCINE - A live attenuated | 2015-09-03 |
| 20150246108 | SEROLOGIC CORRELATES OF PROTECTION AGAINST BACILLUS ANTHRACIS INFECTION - Regions of | 2015-09-03 |
| 20150246109 | COMPOSITIONS, METHODS AND USES FOR POXVIRUS ELEMENTS IN VACCINE CONSTRUCTS AGAINST INFLUENZA VIRUS SUBTYPES OR STRAINS - Embodiments of the present invention generally disclose methods, compositions and uses for generating and expressing poxvirus constructs. In some embodiments, constructs may contain an influenza virus gene segment. In certain embodiments, methods generally relate to making and using compositions of constructs including, but not limited to, poxvirus vaccine compositions having two or more influenza gene segments. In other embodiments, vaccine compositions are reported of use in a subject. | 2015-09-03 |
| 20150246110 | ADJUVANTED INFLUENZA VACCINES INCLUDING CYTOKINE-INDUCING AGENTS - While oil-in-water emulsions are excellent adjuvants for influenza vaccines, their efficacy can be improved by additionally including other immunostimulating agent(s) to improve cytokine responses, such as y-interferon response. Thus, a vaccine comprises (i) an influenza virus antigen; (ii) an oil-in-water emulsion adjuvant; and (iii) a cytokine-inducing agent. | 2015-09-03 |
| 20150246111 | HIV-1 envelope proteins and fragments thereof that possess epitopes recognized by broadly neutralizing antibodies - HIV-1 envelope proteins and fragments that possess naturally occurring and novel engineered epitopes that can be used to elicit (and are recognized by) broadly neutralizing antibodies. | 2015-09-03 |
| 20150246112 | REPLICATING RECOMBINANT ADENOVIRUS VECTORS, COMPOSITIONS, AND METHODS OF USE THEREOF - Replicating recombinant adenovirus vectors derived from human adenovirus serotype 26 or human adenovirus serotype 35 are described. The replicating recombinant adenovirus vectors have attenuated replicative capacity as compared to that of the corresponding wild-type adenovirus. They can be used for stable expression of heterologous genes in vivo. Also described are compositions and methods of using these recombinant adenovirus vectors to induce an immune response in a subject, and vaccinate a subject against an immunogenic human immunodeficiency virus (HIV) infection. | 2015-09-03 |
| 20150246113 | PORCINE PARVOVIRUS 5A, METHODS OF USE AND VACCINE - The present invention provides novel nucleotides sequences, protein sequences, immunogenic compositions, vaccines, and methods that relate to making and using new porcine parvovirus 5A (PPV5A) that infects, inter alia, domestic swine. The compositions and methods provide for the detection of infections by said new virus, monitoring genetic changes in the viral sequences in wild and domestic animals and herds, and making and using novel vaccines for protecting animals from infection by the virus. | 2015-09-03 |
| 20150246114 | LIQUID STABLE VIRUS VACCINES - The present invention discloses liquid stable vaccines that comprise a live attenuated virus, 10-30% sugar additive, and an amino acid. The present invention also discloses the manufacture of such vaccines and methods of protecting an animal by administration of such vaccines. | 2015-09-03 |
| 20150246115 | COMPOSITION COMPRISING CYTOKINE MACRO-AGGREGATES - The present invention provides methods and compositions for the stimulation of immune responses. In particular, the present invention provides compositions (e.g., vaccines) and methods of using the same for the induction of immune responses (e.g., innate and adaptive immune responses (e.g., for generation of host immunity against cancer (e.g., a tumor) or against any type of antigen (e.g. bacterial, viral, parasite-derived)). Compositions and methods of the present invention find use in, among other things, clinical (e.g. prophylactic, therapeutic and preventive medicine (e.g., vaccination)) and research applications. It particularly relates to the area of active specific immunotherapy of cancer (“cancer vaccines”), and provides procedures for the preparation of therapeutic vaccines that can eliminate cancer cells. These vaccines are constructed in such a way that they mimic the release and exchange of cytokines and other bio-molecules on the local cellular level as they occur during induction of natural immune responses. | 2015-09-03 |
| 20150246116 | Combined Treatment with Netrin-1 Interfering Drug and Chemotherapeutic Drug - Pharmaceutical composition comprising a chemotherapeutic drug and a netrin-1 interfering drug or a vector capable of expressing a netrin-1 interfering drug in vivo, in a pharmaceutically acceptable carrier or vehicle. The chemotherapeutic drug is selected from those able to induce over expression of netrin-1 in cancer cells. The combination is associated with synergic anti-cancer effect. | 2015-09-03 |
| 20150246117 | TREATMENT OF TYPE 2 DIABETES AND RELATED CONDITIONS - The present disclosure provides methods of treating diabetic conditions, restoring insulin sensitivity and/or improving regulation of glycemia using an antagonist of VEGF-B, particularly in combination with other anti-diabetic agents such as insulin secretagogues. Compositions are also provided comprising one or more VEGF-B antagonists, particularly in combination with other anti-diabetic agents such as insulin secretagogues. In particular embodiments, the VEGF-B antagonist is an anti-VEGF-B antibody. In further particular embodiments, the other anti-diabetic agent or insulin secretagogue is a DPP-4 inhibitor or a GLP-1R agonist. | 2015-09-03 |
| 20150246118 | LYVE-1 ANTAGONISTS FOR PREVENTING OR TREATING A PATHOLOGICAL CONDITION ASSOCIATED WITH LYMPHANGIOGENESIS - The present invention relates to the prevention or treatment of pathological conditions associated with lymphoangiogenesis (e.g. cancer and eye diseases). The present invention also relates to a method for screening for screening a compound capable of reducing or inhibiting lymphangiogenesis and which may be useful for preventing or treating a pathological condition associated with lymphangiogenesis. | 2015-09-03 |
| 20150246119 | METHODS FOR TREATING OR PREVENTING ASTHMA BY ADMINISTERING AN IL-4R ANTAGONIST - The invention provides methods for treating or preventing asthma and associated conditions in a patient. The methods featured in the invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody. | 2015-09-03 |
| 20150246120 | MOESIN MODULATORS AND USES THEREOF - The present application provides compositions and methods useful for treating and diagnosing diseases and disorders associated with moesin activation. | 2015-09-03 |
| 20150246121 | METHODS OF TREATING CHRONIC INFLAMMATORY DISEASES USING A GM-CSF ANTAGONIST - The invention is based on the discovery that GM-CSF antagonists can be used for the treatment of chronic inflammatory disease, such as rheumatoid arthritis. Accordingly, the invention provides methods of administering a GM-CSF antagonist, e.g., a GM-CSF antibody, and an anti-folate compounds, e.g., methotrexate, to a patient that has RA and pharmaceutical compositions comprising such antagonists. | 2015-09-03 |
| 20150246122 | CANCER TREATMENTS - This document provides methods and materials related to treating cancer (e.g., skin cancer). For example, methods and materials relating to the use of a composition containing albumin-containing nanoparticle/antibody complexes (e.g., ABRAXANE®/anti-VEGF polypeptide antibody complexes) to treat cancer (e.g., skin cancer) are provided. | 2015-09-03 |
| 20150246123 | Combination Therapies with Anti-CD38 Antibodies - The present invention relates to combination therapies with anti-CD38 antibodies. | 2015-09-03 |
| 20150246124 | ANTI-ANGIOGENESIS THERAPY FOR THE TREATMENT OF BREAST CANCER - This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human subjects susceptible to or diagnosed with breast cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents. | 2015-09-03 |
| 20150246125 | Methods and Compositions for Suppressing IgE-Mediated Anaphylaxis - Methods for suppressing IgE-mediated anaphylaxis are provided herein, which include administering to a person in need thereof a combination of at least two therapeutic agents selected from the group consisting of an antihistamine, one or more beta-adrenergic agonists, and one or more tyrosine kinase antagonists. Also provided herein are methods of suppressing IgE-mediated anaphylaxis associated with immunotherapeutic desensitization of a subject, and pharmaceutical compositions for suppressing IgE-mediated anaphylaxis. | 2015-09-03 |
| 20150246126 | MAGNETODYNAMIC ACTIVATION OF 13C-ACYL ISONIAZID AND ISONIAZID AND ETHIONAMIDE DERIVATIVES - The invention provides method of treating a subject suffering from, or at risk of developing, a | 2015-09-03 |
| 20150246127 | Chromophore Combinations for Biophotonic Uses - The present disclosure provides biophotonic compositions and methods useful in phototherapy. In particular, the biophotonic compositions of the present disclosure comprise at least two xanthene dyes. The biophotonic compositions and the method of the disclosure are useful for promoting wound healing and skin rejuvenation, as well as treating acne and other skin conditions. | 2015-09-03 |
| 20150246128 | CONDUCTIVE POLYMER GRAPHENE OXIDE COMPOSITE MATERIALS - A composition includes a composite material including at least one conducting polymer doped with graphene oxide and at least one agent immobilized at least one of (i) on graphene oxide extending from the surface of the composite material or (ii) within the composite material. | 2015-09-03 |
| 20150246129 | PHARMACEUTICAL COMPOSITION - A pharmaceutical composition comprising human insulin, analogues or derivatives thereof, at least one or more amino acids and a halogenide optionally along with one or more pharmaceutically acceptable excipient(s). | 2015-09-03 |
| 20150246130 | ANTIBODY FORMULATION - The present invention provides high concentration liquid formulations of antibodies or fragments thereof that specifically bind to a human interferon alpha polypeptide The formulation provides for an anti-13H5 anti-human interferon alpha antibody A pre-filled syringe containing the formulation is also disclosed. | 2015-09-03 |
| 20150246131 | WATER-BASED PERSONAL LUBRICANTS WITH A SILICONE COMPONENT - The present invention provides a personal lubricant composition that includes (a) at least one silicone-containing component, and (b) a hydrophilic component comprising water and a polyol in respective amounts, which provide advantages such as to tactile and sensory, feel. | 2015-09-03 |
| 20150246132 | NON-COVALENT, SELF-ORGANZING HYDROGEL MATRIX FOR BIOTECHNOLOGICAL APPLICATIONS - The invention relates to the non-covalent, self-organizing hydrogel matrix for biotechnological applications containing a covalent polymer peptide conjugate, wherein the covalent polymer peptide conjugate includes conjugates of two or more peptides that are coupled to a polymer chain and the peptide sequence contains a recurring dipeptide motif (BA) | 2015-09-03 |
| 20150246133 | NOVEL TETRAGALNAC AND PEPTIDE CONTAINING CONJUGATES AND METHODS FOR DELIVERY OF OLIGONUCLEOTIDES - Disclosed herein is a modular composition comprising 1) an oligonucleotide; 2) one or more tetraGalNAc ligands of Formula (I), which may be the same or different; optionally, 3) one or more linkers, which may be the same or different; 4) one or more peptides independently selected from Table 3, which may be the same or different; and optionally, 5) one or more targeting ligands, solubilizing agents, pharmacokinetics enhancing agents, lipids, and/or masking agents. | 2015-09-03 |
| 20150246134 | Biotin Complexes for Treatment and Diagnosis of Alzheimer's Disease - Described herein are compositions and methods for treating or imaging Alzheimer's disease (AD). The compositions comprise a biotin moiety and a siRNA moiety, without the need for a targeting agent such as an antibody, avidin, or streptavidin. In certain embodiments, the compositions further comprise a diagnostic agent. | 2015-09-03 |
| 20150246135 | IMMUNOPARTICLES AND METHODS OF GENERATING AND USING SAME - A pharmaceutical composition comprising an immunoparticle is provided. The pharmaceutical composition comprising a monoclonal secondary antibody immunocomplexed with a primary antibody, wherein said monoclonal secondary antibody is coupled on an outer surface of a particle and wherein said particle is loaded with a pharmaceutical agent. | 2015-09-03 |
| 20150246136 | NOVEL BINDER-DRUG CONJUGATES (ADCs) AND USE OF SAME - The present patent application relates to novel binder-drug conjugates (ADCs) of N,N-dialkylauristatins directed against the target epidermal growth factor receptor (EGFR, gene ID 1956), effective metabolites of these ADCs, methods for producing these ADCs, use of these ADCs for treatment and or prevention of diseases as well as the use of these ADCs to produce pharmaceutical drugs for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic diseases such as cancer, for example. Such treatments may be administered as monotherapy or in combination with other pharmaceutical drugs or other therapeutic measures. | 2015-09-03 |
| 20150246137 | LIPID COATED NANOPARTICLES CONTAINING AGENTS HAVING LOW AQUEOUS AND LIPID SOLUBILITIES AND METHODS THEREOF - Provided herein are compositions that include delivery system complexes comprising a nano-precipitated bioactive compound, wherein the nano-precipitate is encapsulated by a liposome or has at least a portion of its surface coated with a liposome. Because the liposomes contain nano-precipitates of bioactive compounds, the liposomes are capable of utilization in formulating essentially insoluble forms of bioactive agents. Also provided herein are methods for the treatment of a disease or an unwanted condition in a subject, wherein the methods comprise administering the delivery system complexes. | 2015-09-03 |
| 20150246138 | BOLAAMPHIPHILIC COMPOUNDS, COMPOSITIONS AND USES THEREOF - Bolaamphiphilic compounds are provided according to formula I: | 2015-09-03 |
| 20150246139 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF NUCLEAR PROTEINS - The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules. | 2015-09-03 |
| 20150246140 | COMPOSITIONS AND METHODS FOR MODULATING SLEEP AND WAKEFULNESS - In some aspects, the invention relates to methods of treating conditions associated with sleep disorders, comprising administering an agent that modulates the activity of a neuropeptide receptor or a neuropeptide receptor ligand. In some aspects, the invention relates to methods of screening agents that modulate the activity of a neuropeptide receptor in an organism, optionally using cells or organisms comprising a genetic modification that affects a neuropeptide signaling pathway. In some aspects, the invention relates to methods of characterizing a condition associated with a sleep disorder comprising sequencing a nucleic acid encoding either a neuropeptide receptor or a neuropeptide receptor ligand and comparing the sequence with a reference sequence. | 2015-09-03 |
| 20150246141 | DIAGNOSTIC AGENTS WITH ENHANCED SENSITIVITY/SPECIFICITY - Highly sensitive imaging of diseased tissues such as cancer is attractive because it potentially allows for early tumor detection. One of the problems associated with conventional, low molecular weight imaging probes is the limited tumor: background ratio. To circumvent this, imaging probes were conjugated to polymeric carriers and were surprisingly found to accumulate specifically at cancer sites. This invention describes an innovative targeting strategy for the selective identification of solid tumors by means of polymer-NIR fluorochrome conjugates which accumulate selectively within cancerous tissue relative to normal tissue. | 2015-09-03 |
| 20150246142 | IMAGING AGENTS - Provided herein is technology relating to imaging agents and particularly, but not exclusively, to methods of manufacturing fluorine-18-labeled phenethylguanidines and uses thereof. | 2015-09-03 |
| 20150246143 | SYSTEM AND METHOD FOR QUANTITATIVE MAPPING OF MITOCHONDRIAL COMPLEX 1 - A system and method is provided for processing a positron emission tomography (PET) image of a subject having received a dose of a radiotracer that serves as chemical analog of an MC-I inhibitor. Specifically, the processing may includes identifying portions of the at least one PET image that represent MC-I expression levels. | 2015-09-03 |
| 20150246144 | LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) BIOLOGICAL EVALUATION, AND USE OF IMAGING AGENTS - The prostate-specific membrane antigen (PSMA) is increasingly recognized as a viable target for imaging and therapy of cancer. Various 99mTc/Re-labeled compounds were prepared by attaching known Tc/Re chelating agents to an amino-functionalized PSMA inhibitor with or without a variable length linker moiety. Ex vivo biodistribution and in vivo imaging demonstrated the degree of specific binding to engineered PSMA+PC3 PIP tumors. | 2015-09-03 |
| 20150246145 | Labelled adrenomedullin derivatives and their use for imaging and therapy. - The present invention relates to an adrenomedullin derivative including an adrenomedullin peptide, or a fragment thereof chelated or otherwise bound to at least one active agent. Examples of active agents include a paramagnetic element, a radioactive element and a fibrinolytic agent, among others. Paramagnetic agents have a distribution that is relatively easily shown through Magnetic Resonance Imaging (MRI). Radioactive agents have applications in imaging and delivery of radiations, depending on the specific element included in the active agent. Delivery of fibrinolytic agents mainly to a specific organ, such as for example to the lungs, allows to substantially improve the specificity and efficacy of thrombolytic therapy by allowing local delivery of the fibrinolytic agent, thereby reducing the risks of major bleeding in the therapy of the organ. If the organ is the lungs, a non-limiting example of pathology treatable with the fibrinolytic agent is pulmonary embolus. | 2015-09-03 |
| 20150246146 | METHODS AND COMPOSITIONS FOR ENZYME-MEDIATED SITE-SPECIFIC RADIOLABELING OF GLYCOPROTEINS - Provided herein are methods, compositions and kits for use in the site-specific labeling of glycoproteins comprising a combination of enzyme-mediated incorporation of modified sugars comprising a chemical handle and cycloaddition chemistry with a labeling molecule comprising a reactive group, a metal ion chelator, and/or a fluorophore. | 2015-09-03 |
| 20150246147 | METHOD FOR COLLECTING METAL-CONTAINING FULLERENE - A method for recovering an endohedral metallofullerene comprises a complexation step of adding a Lewis acid comprising titanium halide or tin halide to a reaction solution formed by dissolving crude fullerenes in a solvent, thereby forming a complex of the endohedral metallofullerene and the Lewis acid, a filtering step of filtering the reaction solution to separate the complex, and a washing step of removing the Lewis acid from the complex to obtain the endohedral metallofullerene. The obtained endohedral metallofullerene is soluble in a solvent. This method provides a high recovery yield of the endohedral metallofullerene. | 2015-09-03 |
| 20150246148 | COMPACT SYSTEM WITH HIGH HOMOGENEITY OF THE RADIATION FIELD - The invention relates to a system for treating gases and/or liquids with radiation or for detecting radiation in gases and/or liquids, including at least one optical system and a reactor. The reactor has a hollow body shape which includes lateral surfaces, connecting parts, and an inner chamber which may be open to the front and rear sides, through which a medium flows or in which the medium is present. The reactor is designed, at least partially, in the form of a radiation reflector and is divided into first and second functional areas. This enables a particularly homogeneous radiation distribution in the inner chamber of the reactor, which increases the efficiency of the treatment or detection. Also, due to this arrangement, the system is more compact. | 2015-09-03 |
| 20150246149 | METHOD AND APPARATUS FOR DISINFECTING AND/OR SELF-STERILIZING A STETHOSCOPE USING PLASMA ENERGY - A method and apparatus for disinfecting and/or self-sterilizing at least a portion of the surface of a stethoscope is provided. Methods and devices are provided by which a device or apparatus can generate a sterilizing plasma such that a stethoscope, or portion of a stethoscope, can be placed within or near the device or apparatus so that the plasma disinfects and/or sterilizes and/or decontaminates at least a portion of the stethoscope. A method and apparatus are disclosed for providing a self-disinfecting and/or self-sterilizing and/or self-decontaminating stethoscope and stethoscope disinfecting and/or sterilization apparatus for disinfecting and/or sterilizing, respectively, all or at least a portion of a stethoscope. | 2015-09-03 |
| 20150246150 | METHOD FOR REMOVING PARTICULATE MATTER IN INDOOR ENVIRONMENTS - Method for removing all types of particulate matter with exclusion of biological multiplying microorganisms in indoor environments characterized by comprising the following two steps:—the atomization of compounds that oxidize particulate matter to form complexes and to precipitate them;—the atomization of a liquid containing a mixture of spores of Gram-positive aerobic and/or of facultative anaerobic spore formers to act as nuclei for extra precipitation, to cover the precipitated particulate matter; and to metabolize precipitated particles and to take up precipitated particles by the Gram-positive bacteria/thereby preventing the precipitated particles to become airborne again;—whereby the drop size in both atomization steps is held between 5 and 50 μm to yield a dry nebula. | 2015-09-03 |
| 20150246151 | DECONTAMINATION SYSTEM FOR ON-BOARD A VEHICLE - A decontamination system on-board a vehicle may comprise a reservoir on-board a vehicle and the reservoir contains a disinfectant solution. The system may also include a pressurized air supply on-board the vehicle; and, one or more nozzles secured on-board the vehicle and in fluid communication with the reservoir and the pressurized air supply. In addition, one or more pumps may be on-board the vehicle and the one or more pumps are in fluid communication with the reservoir and the one or more nozzles. The system may also include a programmable controller in signal communication with the one or more pumps and pressurized air supply to activate the one or more pumps and pressurized air supply to deliver the disinfectant solution and pressurized air to the one or more nozzles, wherein the solution is dispersed in atomized form in an interior space of the vehicle to be decontaminated. | 2015-09-03 |
| 20150246152 | LIGHT SOURCE DISINFECTION IN A PNEUMATIC TRANSPORT SYSTEM - Provided herein are systems, apparatuses and methods for use in disinfecting pneumatic tube system (PTS) components and/or disinfecting air displaced during the operation of a PTS. More specifically, various aspects are directed to the use of light source disinfection systems for disabling bacteria, viruses and/or other micro-organisms (hereafter “pathogens”) in a PTS. The light source disinfection systems allow of cleaning pneumatic carriers, cleaning the interior of pneumatic tubes and PTS components and/or cleaning air, which is used to propel pneumatic carriers in a PTS. | 2015-09-03 |
| 20150246153 | ABSORBENT ARTICLE - An objective of the present invention is to provide an absorbent article that prevents wetting of the outer sides or surrounding area of the absorbent article due to condensation formed by water vapor escaped from inside the absorbent article. The present invention provides an absorbent article comprising: an absorbent body composed of at least one absorption layer, wherein the absorbent body includes a hydrophobized adsorbent and (a) a water absorbent resin powder having an absorption speed in a range from 6 seconds to 60 seconds determined by a vortex method. | 2015-09-03 |
| 20150246154 | PROCESS AND DRESSING - An anti-microbial absorbent chitosan, optionally in the form or fibres, derivatised by reaction with an optionally substituted alkylene oxide, a non-woven fabric and an absorbent device comprising the derivatised chitosan, methods for the preparation of such a chitosan, non-woven fabric and an absorbent device, and the use of said absorbent device in wound care. | 2015-09-03 |
| 20150246155 | Methods and Compositions for Promoting Wound Healing - The present invention provides methods and compositions that use the combination of Tris and EDTA to inhibit the growth of microorganisms at the site of a wound or burn, and/or to promote the healing of a wound or burn, and/or to reduce the sensation of pain at the site of a wound or burn. The amount of Tris and EDTA applied to a wound or burn can be selected to achieve one or more of the foregoing effects. | 2015-09-03 |
| 20150246156 | Metal Implant Produced From a Method for Processing a Surface of a Metal Implant - A metal implant produced from a method for treating a surface of a metal implant includes a metal layer, an oxide layer formed on a surface of the metal layer, and a macromolecular anti-adhesion layer formed on an outer surface of the oxide layer. The macromolecular anti-adhesion layer is formed of polyethylene glycol. | 2015-09-03 |
| 20150246157 | SCAFFOLD FOR CARDIAC PATCH - A biocompatible and biodegradable medical device patch actuating primarily as soft tissue structural reinforcement. The device has a layered architecture, where the primary serves as suturing layer and mechanical support to a thick porous scaffold which can be coated with a mimic-like extra cellular matrix (ECM). The device can be provided to the end user under the format of independent layers that can be cut and assembled to the specific need to the end user and patient. The layers are assembled without the need of any adhesive. Totally haemocompatible and of behavior superior to polytetrafluoroethylene used for any soft tissue repaired, the field of this invention is demonstrated for cardiovascular therapy but should not be limited to it. It is of practical relevance of vein, tendon and hernias and dermal treatments. | 2015-09-03 |
